Swiss Medica Inc., Innovative Products That Improve Peoples' Lives

8/4/2005 3:04:26 PM ET

WAL-MART CANADA CORP. NOW OFFERING SWISS MEDICA'S O24™ PAIN NEUTRALIZER

FOR IMMEDIATE RELEASE

Stock Symbol: OTC BB: SWME

Aug 4, 2005

WAL-MART CANADA CORP. NOW OFFERING SWISS MEDICA'S O24™ PAIN NEUTRALIZER

TORONTO-- Aug. 4, 2005--Swiss Medica, Inc. is pleased to announce that Wal-Mart Canada Corp. is now

offering O24™ Pain Neutralizer nationwide in both the 1 ounce bottle size and the convenient 20-count

towelettes.

"Swiss Medica is pleased that our line of O24™ products will be available in another key retailer," announced

Anne Dundon, Vice President Sales. "We look forward to our partnership with Wal-Mart Canada Corp."

About Swiss Medica Inc.

Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our

market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a

world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please

visit our websites at www.swissmedica.com,

and

Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain

relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by

healthcare professionals and athletes in the United States, Canada and in Europe. O24™ is widely available

throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit

, for ordering details and store locators for the nearest pharmacy.

Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS

Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce

changes in mood and appetite that women experience during the premenstrual period. Customers can also visit:

for additional information and ordering details.

Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United

States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking

statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close

transactions being contemplated, risks related to international sales and potential foreign currency exchange

fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological

changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's

periodic reports filed with the United States Securities and Exchange Commission and other regulatory

authorities.

For more information, please contact:

Swiss Medica Inc.

Investor Relations Contact:

David Jones

(866) 485-4243